Diabetes

The AJMC^® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Gestational diabetes | Image credit: Phushutter - stock.adobe.com

Questionnaire Evaluates Obstetric Nurse Competency in Managing Gestational Diabetes

By Pearl Steinzor

May 8th 2025

A validated questionnaire assesses skills, knowledge, and attitudes for effective gestational diabetes management.

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Rural health sign | Image credit: BJP7images - stock.adobe.com

FQHCs Show Low Engagement in Hypertension, Diabetes Trials

By Pearl Steinzor

April 15th 2025

AI representation of housing stability | Image credit: GoldPumaze - stock.adobe.com

Housing Instability Linked to Worse Type 2 Diabetes Outcomes

By Pearl Steinzor

April 14th 2025

Diabetes concept | Image credit: Sherry Young - stock.adobe.com

GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

By Pearl Steinzor

April 9th 2025

More News

November 4th 2019

Final ICER Report Finds Empagliflozin More Cost Effective Than Oral Semaglutide for Type 2 Diabetes

Mary Caffrey

Oral semgalutide’s price, along with its potential for adverse events, caused ICER to give empagliflozin the edge in cost effectiveness as physicians and health plans evaluate which type 2 diabetes therapy should be given after metformin.

November 1st 2019

This Week in Managed Care: November 1, 2019

This week, the top managed care stories included a report from the FDA considering how to avoid drug shortages; a white paper finds rising comfort with telehealth even as use of digital health tools stagnates; data show a spike in the number of uninsured children.

November 1st 2019

Final Rule on New Kidney Care Model Seeks Reduced Spending on ESRD

Mary Caffrey

Rising rates of obesity and diabetes have raised concerns that more people could be headed for end-stage renal disease (ESRD); thus, Medicare has been seeking ways to reduce the cost of care and to improve the quality of life for people on dialysis. Scientists are focusing on whether more patients with early-stage type 2 diabetes should take sodium glucose co-transporter 2 inhibitors, which have been shown to slow renal decline.

October 31st 2019

Senators Ask CMS to Change Course on Virtual Medicare DPP

Mary Caffrey

The 19 signers of the letter to HHS Secretary Alex Azar and CMS Administrator Seema Verma include Senate Finance Committee members and lawmakers from states with high rates of diabetes and obesity.

October 27th 2019

Podcast: This Week in Managed Care—GOP Releases Part of Its Healthcare Plan and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

October 25th 2019

What We're Reading: Meth Overdoses Surge; Oklahoma Medicaid Campaign; FTC Sues for Diabetes Claims

AJMC Staff

A CDC report said that, overall, fentanyl continues to drive drug overdose deaths, but in almost half of the country, methamphetamine is the leading killer; backers of Medicaid expansion in Oklahoma said they submitted more than enough signatures to get the measure on the ballot in 2020; the Federal Trade Commission is suing publishers of "The Doctor's Guide to Reversing Diabetes in 28 Days" on the grounds that they are falsely promising a cure without dietary changes or exercise and stating that those changes will make diabetes worse.

October 25th 2019

This Week in Managed Care: October 25, 2019

This week, the top managed care news included the average Affordable Care Act premiums falling 4%; the FDA approving a triple combination treatment for cystic fibrosis; House Republicans releasing part 1 of their healthcare plan.

October 24th 2019

Adding Empagliflozin to Insulin Cuts A1C in Type 1 Diabetes, Reduces CV Risk in Study

Mary Caffrey

The advantage of empagliflozin, and the sodium glucose cotransporter 2 class generally, is that its unique mechanism expels excess glucose through the urine, thus offering the possibility of reducing glucose variability—eliminating the “roller coaster” effect that many with type 1 diabetes experience that can cause long-term microvascular damage.

October 20th 2019

Black Patients With Diabetes May Have Greater Hospital Readmission Risk, Study Finds

Alison Rodriguez

Black patients with diabetes may have a significantly higher risk of readmission to hospitals than other ethnic and racial minorities due to the high burden and complications of the disease, according to research published in JAMA Network Open.

October 16th 2019

Abbott, Omada Health to Combine Digital Coaching With CGM for Those With Type 2 Diabetes

Mary Caffrey

Omada Health, a longtime leader in digital health coaching for diabetes prevention and type 2 diabetes (T2D) care, and Abbott, maker of the FreeStyle Libre, said the partnership will “create a new paradigm” in T2D management.

October 14th 2019

Empagliflozin Beats Pair of DPP-4s in Cost-Effectiveness for Patients With Type 2 Diabetes, CVD

Mary Caffrey

The authors say their findings align with other analyses showing the cost-effectiveness of sodium glucose co-transporter 2 (SGLT2) inhibitors.

October 14th 2019

What We're Reading: Judge Denies Trump Immigration Proposal; Diabetes Risk Test Eyed; 29 Deaths Now Tied to Vaping

AJMC Staff

Federal judges denied a Trump administration proposal to deny green cards to immigrants requiring public benefits; researchers aim to develop a test to assess hereditary diabetes risk; vaping-related deaths rise to 29 nationwide.

October 10th 2019

What We're Reading: FDA Clears Dexcom G6 Pro CGM; Cleveland Clinic and Oscar Expand Health Plans; Planned Parenthood Election Spending

AJMC Staff

FDA clears Dexcom G6 Pro CGM System for use among healthcare professionals; Cleveland Clinic and Oscar expand healthcare coverage to 3 additional Ohio counties; Planned Parenthood announces record-high election spend to support Democratic and pro-abortion candidates.

October 8th 2019

Next Chapter of Intarcia's Mini Pump for Diabetes Begins as FDA Accepts Resubmitted NDA

Mary Caffrey

More than 2 years after the FDA derailed the trajectory of its novel treatment system for type 2 diabetes (T2D), Intarcia Therapeutics today announced that regulators have accepted a resubmitted new drug application for the mini pump that delivers a continuous dose of exenatide.

October 7th 2019

Experimental Drug Reverses Fatty Liver Disease, Cuts Cholesterol

Mary Caffrey

A study last year pointed to empagliflozin as the best choice for patients who have type 2 diabetes and non-alcoholic fatty liver disease.

October 6th 2019

Podcast: This Week in Managed Care—Hospital Readmission and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

October 4th 2019

This Week in Managed Care: October 4, 2019

This week, the top managed care news included Medicare cuts hospital payments over readmissions; a second-generation chimeric antigen receptor T-cell therapy shows promise; a diabetes drug is approved to prevent kidney failure for the first time.

October 1st 2019

FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure

Mary Caffrey

The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic kidney disease.

September 29th 2019

Podcast: This Week in Managed Care—State, Federal Crackdowns on Vaping, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

September 27th 2019

Impact of Switching Analogue Insulin to Human Insulin in Diabetes

Kyunghwa Park, PharmD Angela Eng Jeong, PharmD Eric Guenther-Gleason, PharmD, MS Sachin H. Jain, MD, MBA

Converting from analogue insulin to human insulin is associated with a clinical insignificant increase in glycated hemoglobin of 0.16% but with improved insulin adherence.

September 27th 2019

Examining the Reality of What Insulin Costs Do to Patients

Robert A. Gabbay, MD, PhD, FACP

The editor-in-chief of Evidence-Based Diabetes Management™ introduces the special issue, Perspectives on Insulin Pricing, and shares that he has seen rationing among his own patients.

September 27th 2019

This Week in Managed Care: September 27, 2019

This week, the top managed care news included state and federal crackdowns on vaping that forced out the president of Juul; FDA approved a groundbreaking diabetes treatment; Medicare Advantage premiums will decline for 2020.

September 27th 2019

Sara Karlovitch

From the Center for Biosimilars®, a discussion on giving patients new, less expensive alternatives for managing diabetes.

September 27th 2019

How Prepared Is the United States for the Transition of Insulins to Regulation as Biologics?

Kelly Davio

From The Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.

September 26th 2019

Could Aiming Insulin at the Liver Be an Answer to Using Less?

Mary Caffrey

A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.

September 26th 2019

Gathering Evidence on Insulin Rationing: Answers and Future Questions

Mary Caffrey

The results of a study published last year from authors at Yale Diabetes Center suggest that rationing is more common than the healthcare system wants to admit. Senior author Kasia Lipska, MD, MHS, says the findings raise a whole new set of questions.

September 26th 2019

JDRF's Kowalski Sees Hope in Bipartisan Support for Insulin Pricing Reform

Andrew Smith

Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.

September 25th 2019

As a Child, Diabetes Was Hard to Accept. Now She's Living With the Complications

Jaime Rosenberg

The diagnosis of diabetes can be hard for a teenager to accept. Add insulin affordability to the mix, and by the time a young adult learns to live with the disease, the complications have already arrived.

September 20th 2019

FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form

Mary Caffrey

Novo Nordisk officials believe the new therapy will fufill an unmet need for patients with type 2 diabetes and obesity who need a GLP-1 receptor agonist but do not wish to use an injectable drug.

September 14th 2019

Study Finds Lifestyle Intervention Aimed at Weight Loss May Reduce Cardiovascular Events in Type 2 Diabetes

Alison Rodriguez

Intensive lifestyle intervention focusing on weight loss may reduce cardiovascular events in selected type 2 diabetes patients yet have a detrimental treatment effect in some, according to recent research.

...

16 17 18 19 20 21 22 23 24

...

98 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions